This Article Full Text Full Text (PDF) All Versions of this Article: 46/1/144    most recent 01.HYP.0000170464.41776.98v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masuo, K. Articles by Tuck, M. L. Search for Related Content PubMed PubMed Citation Articles by Masuo, K. Articles by Tuck, M. L. Related Collections Clinical Studies

(Hypertension. 2005;46:144.)
© 2005 American Heart Association, Inc.

Original Articles

Lys418Asn Polymorphism of the 2-Adrenoceptor Gene Relates to Serum Uric Acid Levels But Not to Insulin Sensitivity

Kazuko Masuo; Tomohiro Katsuya; Yuxiao Fu; Hiromi Rakugi; Toshio Ogihara; Michael L. Tuck

From the Human Neurotransmitter Laboratory (K.M.), Baker Heart Research Institute, Melbourne, Victoria, Australia; Department of Geriatric Medicine (K.M., T.K., Y.F., H.R., T.O.), Osaka University Graduate School of Medicine, Suita, Japan; and Endocrinology and Metabolism Division (M.L.T.), Sepulveda VA Medical Center and the David Geffen UCLA School of Medicine, Los Angeles, Calif.

Correspondence to Kazuko Masuo, MD, PhD, Baker Heart Research Institute, PO Box 6492 St Kilda Rd Central, Melbourne, Victoria 8008, Australia. E-mail kmasuo{at}baker.edu.au

Hyperuricemia is associated with cardiovascular risk. The present study examines the association between serum uric acid (UA) elevation and the 2-, ß2-, and ß3-adrenoceptor polymorphisms. In 219 nonobese, normotensive, normouricemic (serum UA <6.5 mg/dL at entry) men, serum UA, plasma norepinephrine (NE), the homeostasis model assessment of insulin resistance (HOMA-IR), body mass index, total body fat mass, the 2A(Lys418Asn)-, ß2(Arg16Gly, Gln27Glu)-, and ß3(Trp64Arg)-adrenoceptor polymorphisms were measured annually over 5 years. Hyperuricemia was defined as a serum UA level of mean+1 SD of 5.0 mg/dL in the participants. At entry, there were 36 subjects who had hyperuricemia and 183 who had normal UA levels. A significant UA elevation for 5 years was defined as an increase in 10% in UA levels. There were 82 subjects who had significant UA elevations. The subjects who had hyperuricemia at entry in addition to the subjects who had significant UA elevations over the 5-year period carried a significantly higher frequency of the Asn418 allele of Lys418Asn. Additionally, subjects carrying the Asn418 allele had higher UA and plasma NE and greater elevations in UA over the study period, but HOMA-IR was similar. Insulin resistance at entry and during the study was associated with Arg16Gly polymorphisms but not with Lys418Asn polymorphisms. In conclusion, the Asn418 allele of Lys418Asn is associated with either established hyperuricemia or the progressive elevation of UA over time. This polymorphism was not associated with insulin resistance in nonobese, normotensive individuals. Although hyperuricemia is of known relevance to insulin resistance, it appears to have different genetic determinants from insulin resistance in terms of adrenoceptor polymorphisms.

Key Words: uric acid • polymorphism • insulin resistance

This article has been cited by other articles:

				N. Dalbeth and T. Merriman Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout Rheumatology, March 1, 2009; 48(3): 222 - 226. [Abstract] [Full Text] [PDF]